About RNADD

A Leading Global Molecular Diagnostic Platform

  • Contribute to the early detection and prevention of infectious disease transmission

  • Leverage our proprietary AntiSense molecular RNA diagnostic platform across multiple infectious disease diagnostic categories

  • Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic testing kits that will democratize testing for use at point of care and in home

Platform Direction

The Company’s AntiSense molecular diagnostic platform is being developed for use at Point of Care (POC) and In Home (HUT) to test on-site for a wide range of viral and other diseases.

The Company’s first products are AntiSense molecular diagnostic test kits that accurately, quickly and affordably detect respiratory infections, including Covid-19 in less than 5 minutes.

Applications & Uses

Deployed at the point of entry of high traffic venues such as airports, shopping malls, office buildings, sporting venues, manufacturing plants, hospitals, pharmacies, nursing and long-term care homes the AntiSense POC molecular diagnostic test kit will contribute to safe reopening of the economy. The AnitSense HUT molecular diagnostic test kit will further allow for quick, easy, and accurate in home self-testing, allowing the economy to remain open.

Airports
Office Buildings
Shopping Malls
Manufacturing Sites
Hospitals
Nursing/ Care Homes
Sporting Venues
Pharmacies

Exclusive Global License

RNA Disease Diagnostics Secures Exclusive License to Ground-Breaking RNA-Based Molecular Lateral Flow Assay Technology

November 9, 2021

RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today that it has secured an exclusive global license to a rapid ribonucleic acid (“RNA”)-based molecular Lateral Flow Assay (“LFA”) technology jointly owned by the University of Maryland, Baltimore (“UMB”) and the University of Maryland, Baltimore County (“UMBC”).

Read More

Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board

September 2, 2021

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D. to its Advisory Board.

Read More